Myomo (MYO) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MYO shares.
View MYO analyst ratings or view top-rated stocks.

2 analysts have issued twelve-month price targets for Myomo's stock. Their MYO share price forecasts range from $1.60 to $1.60. On average, they predict the company's stock price to reach $1.60 in the next year. This suggests a possible upside of 244.1% from the stock's current price.
View analysts price targets for MYO or view top-rated stocks among Wall Street analysts.

Myomo's stock was trading at $0.5194 at the beginning of the year. Since then, MYO shares have decreased by 10.5% and is now trading at $0.4650.
View the best growth stocks for 2023 here.

Myomo saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 38,700 shares, a decline of 69.8% from the April 15th total of 128,200 shares. Based on an average daily trading volume, of 822,500 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.2% of the company's stock are sold short.
View Myomo's Short Interest.

Myomo, Inc. (NYSEAMERICAN:MYO) posted its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. The firm had revenue of $3.45 million for the quarter, compared to the consensus estimate of $3.33 million. Myomo had a negative net margin of 69.71% and a negative trailing twelve-month return on equity of 123.53%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myomo investors own include Genocea Biosciences (GNCA), Agile Therapeutics (AGRX), Sarepta Therapeutics (SRPT), Aclaris Therapeutics (ACRS), Remark (MARK), Protalix BioTherapeutics (PLX), Synergy Pharmaceuticals (SGYP), VBI Vaccines (VBIV), Athersys (ATHX) and Anavex Life Sciences (AVXL).

Myomo trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MYO."

Myomo's stock is owned by a number of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (9.56%), Virtu Financial LLC (0.52%), Renaissance Technologies LLC (0.33%) and Two Sigma Securities LLC (0.16%). Insiders that own company stock include David A Henry, Micah Mitchell, Paul R Gudonis and Thomas Aloysius Jr Crowley.
View institutional ownership trends.

Shares of MYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MYO stock can currently be purchased for approximately $0.47.

Myomo (NYSEAMERICAN:MYO) has a market capitalization of $9.73 million and generates $15.56 million in revenue each year. The company earns $-10,720,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

Myomo's mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The official website for the company is myomo.com. The company can be reached via phone at (617) 996-9058 or via email at ir@myomo.com.